CX-8998 for Absence Seizures — T-WAVE  

Epilepsy Clinical Trial

Official title: A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures

Status Completed

Clinical Trial Summary

This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.

Clinical Trial Description

This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication. Subjects will participate for a total of up to 9 weeks, including screening, the 4-week treatment period and follow-up. ;

Related Conditions & MeSH terms

• Epilepsy
• Epilepsy, Absence
• Seizures

• NCT number: NCT03406702
• Study type: Interventional
• Source: Jazz Pharmaceuticals
• Status: Completed
• Phase: Phase 2
• Start date: February 25, 2018
• Completion date: March 29, 2019